Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
lundi, octobre 19
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Allarity Therapeutics Inc
ALLR
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$0.8700
-0.025
-2.79%
Dern. MÀJ: Oct 19, 11:28 AM
$0.8510
-0.044
-4.92%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Comparer
Rapport sur les stocks
Privacy Manager
Allarity Therapeutics Financials
Allarity Therapeutics (ALLR) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Allarity Therapeutics Q2 EPS $(0.21) Beats $(0.25) Estimate
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.25) by 16 percent. This is a 40 percent decrease over losses of $(0.15) per share from
Benzinga Newsdesk
PRO
Allarity Therapeutics Q1 EPS $(0.17) Beats $(0.22) Estimate, Sales $25.000K
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.22) by 22.73 percent. This is a 32 percent increase over losses of $(0.25) per share
Benzinga Newsdesk
PRO
Allarity Therapeutics Q4 EPS $(0.21), Inline, Sales $320.000K
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.21) per share which met the analyst consensus estimate. This is a 87.79 percent increase over losses of $(1.72) per share from the same period last
Benzinga Newsdesk
PRO
Allarity Therapeutics Q3 EPS $(0.19) Beats $(0.21) Estimate
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 97.54 percent increase over losses of $(7.71) per share
Benzinga Newsdesk
Crude Oil Down 2%; US Durable Goods Orders Decline In July
Avi Kapoor
US Stocks Mixed; American Woodmark Posts Downbeat Sales
Avi Kapoor
